|
|
Tumour-derived exosomes (TEXs) |
|
Vaxjo ID |
331 |
|
Vaccine Adjuvant Name |
Tumour-derived exosomes (TEXs) |
|
Adjuvant VO ID |
VO_0005721
|
|
Description |
The paper studies whether tumor-derived exosomes primed by IRF-1 can boost antitumor immunity. It isolates IRF-1- or IFN-γ-induced exosomes, analyzes IL-15Rα and MHC class I expression, and evaluates their antitumor effects in mice when combined with a CpG adjuvant. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Tumour-derived exosomes (TEXs) |
|
Preparation |
Exosomes were isolated via ultracentrifugation from tumour cells infected with IRF-1-expressing adenovirus (IRF-1-Exo) or treated with interferon-纬 (IFN-Exo). |
|
Function |
Exosomes from tumor cells expressing IRF-1 or treated with IFN-γ were isolated and analyzed for IL-15Rα and MHC-I. When combined with CpG adjuvant and injected into tumor models, these exosomes were tested for antitumor effects. Tumors were examined by immunofluorescence, and splenocytes were co-cultured with tumor cells to measure IFN-γ^+ and granzyme B^+ CD8^+ T cells by flow cytometry. |
| References |
Yang et al., 2018: Yang MQ, Du Q, Varley PR, Goswami J, Liang Z, Wang R, Li H, Stolz DB, Geller DA. Interferon regulatory factor 1 priming of tumour-derived exosomes enhances the antitumour immune response. British journal of cancer. 2018; 118(1); 62-71. [PubMed: 29112686].
|
|
